Safety and immunogenicity of booster immunization with 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3161090 38 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Safety and immunogenicity of booster immunization with 7-valent
pneumococcal conjugate vaccine in children with idiopathic nephrotic
syndrome
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Safety and immunogenicity of a booster dose of 7-valent pneumococcal
conjugate vaccine (PCV7) were evaluated in 29 patients with idiopathic
nephrotic syndrome (INS), who had been primed 12 months earlier with one
dose of PCV7. PCV7 was not associated with increased risk of INS relapse
(RR = 0.77, p = 0.8) and serotype-specific antibodies increased in all
subjects at 1 month (p < 0.01). The quantitative characteristics of
immune response and the effect of treatment with mycophenolate mofetil
and/or cyclosporine A following booster PCV7 were similar with primary
response. Additional PCV7 doses could be safely given in children with
INS to increase circulating antibodies above the protective threshold.
(C) 2014 Elsevier Ltd. All rights reserved.
Έτος δημοσίευσης:
2014
Συγγραφείς:
Liakou, Christina D.
Askiti, Varvara
Mitsioni, Andromachi and
Stefanidis, Constantinos J.
Theodoridou, Maria C.
Spoulou, Vana
I.
Περιοδικό:
Vaccine
Εκδότης:
Elsevier Sci Ltd, Exeter, United Kingdom
Τόμος:
32
Αριθμός / τεύχος:
12
Σελίδες:
1394-1397
Λέξεις-κλειδιά:
Idiopathic nephrotic syndrome; Pneumococcal conjugate vaccine; Safety;
Booster vaccination
Επίσημο URL (Εκδότης):
DOI:
10.1016/j.vaccine.2013.11.106
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.